Amarin Corporation PLC - Asset Resilience Ratio

Latest as of March 2026: 27.37%

Amarin Corporation PLC (AMRN) has an Asset Resilience Ratio of 27.37% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Amarin Corporation PLC (AMRN) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$176.76 Million
Cash + Short-term Investments

Total Assets

$645.76 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2000–2025)

This chart shows how Amarin Corporation PLC's Asset Resilience Ratio has changed over time. See net asset quality index of Amarin Corporation PLC to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Amarin Corporation PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Amarin Corporation PLC stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $176.76 Million 27.37%
Total Liquid Assets $176.76 Million 27.37%

Asset Resilience Insights

  • Very High Liquidity: Amarin Corporation PLC maintains exceptional liquid asset reserves at 27.37% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Amarin Corporation PLC Industry Peers by Asset Resilience Ratio

Compare Amarin Corporation PLC's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
AstraZeneca PLC
NASDAQ:AZN
Drug Manufacturers - General 0.10%
AstraZeneca PLC
NYSE:AZN
Drug Manufacturers - General 0.10%
Novartis AG
SW:NOVN
Drug Manufacturers - General 0.08%
Pfizer Inc
NYSE:PFE
Drug Manufacturers - General 5.48%
Pfizer Inc
SA:PFIZ34
Drug Manufacturers - General 5.48%
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
Drug Manufacturers - General 1.97%
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
Drug Manufacturers - General 5.37%
Firebrick Pharma Ltd
AU:FRE
Drug Manufacturers - General 0.29%

Annual Asset Resilience Ratio for Amarin Corporation PLC (2000–2025)

The table below shows the annual Asset Resilience Ratio data for Amarin Corporation PLC.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 25.04% $167.93 Million $670.77 Million -0.23pp
2024-12-31 25.27% $173.18 Million $685.35 Million +10.67pp
2023-12-31 14.60% $121.41 Million $831.68 Million +4.25pp
2022-12-31 10.35% $91.69 Million $886.18 Million -11.62pp
2021-12-31 21.97% $234.67 Million $1.07 Billion -10.53pp
2020-12-31 32.50% $313.97 Million $966.02 Million +32.13pp
2017-12-31 0.37% $600.00K $161.60 Million +0.01pp
2016-12-31 0.36% $600.00K $167.00 Million +0.01pp
2015-12-31 0.35% $600.00K $173.46 Million 0.00pp
2014-12-31 0.35% $600.00K $171.11 Million -0.05pp
2013-12-31 0.40% $1.00 Million $252.48 Million -7.79pp
2008-12-31 8.18% $3.00 Million $36.66 Million +8.11pp
2001-12-31 0.07% $64.00K $90.99 Million -30.90pp
2000-12-31 30.97% $15.05 Million $48.60 Million --
pp = percentage points

About Amarin Corporation PLC

NASDAQ:AMRN USA Drug Manufacturers - General
Market Cap
$330.68 Million
Market Cap Rank
#14666 Global
#3424 in USA
Share Price
$15.77
Change (1 day)
+3.96%
52-Week Range
$12.54 - $20.25
All Time High
$24.12
About

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The compa… Read more